Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – ... | June 18, 2023
In several abstracts presented at this year's American Academy of Neurology Annual Meeting, Mitzi Joi Williams, MD, FAAN, Joi Life Wellness Neurology Clinic, explores multiple sclerosis–related outcomes in diverse patient populations.
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets The U.S. Food and Drug Administration ... | April 11, 2023
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate